Breaking News Instant updates and real-time market news.

GILD

Gilead

$79.12

1.26 (1.62%)

, MRK

Merck

$62.41

0.5 (0.81%)

07:47
10/03/16
10/03
07:47
10/03/16
07:47

AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink

Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.

GILD

Gilead

$79.12

1.26 (1.62%)

MRK

Merck

$62.41

0.5 (0.81%)

ABBV

AbbVie

$63.07

0.25 (0.40%)

  • 04

    Oct

  • 07

    Oct

  • 25

    Oct

  • 06

    Nov

  • 11

    Nov

GILD Gilead
$79.12

1.26 (1.62%)

09/27/16
LEER
09/27/16
DOWNGRADE
Target $94
LEER
Market Perform
Gilead downgraded to Market Perform from Outperform at Leerink
Leerink analyst Geoffrey Porges downgraded Gilead Sciences to Market Perform from Outperform and lowered his price target for the shares to $94 from $112. The biotech closed yesterday down 75c to $80.62. The analyst says he's now "outright bearish" on the company's Hepatitis C virus business. Gilead's HCV revenues will "decline faster, and farther," than the current consensus estimates forecast, Porges tells investors in a research note.
09/22/16
JANY
09/22/16
NO CHANGE
Target $64
JANY
Buy
Galapagos drug more important to Gilead after trial halt, says Janney Capital
Janney Capital analyst Debjit Chattopadhyay said Gilead Sciences' (GILD) termination of its combined Phase 2/3 study of GS-5745 in ulcerative colitis implies that Galapagos (GLPG) filgotinib is now potentially more important to Gilead's growth prospects. The analyst, who thinks upcoming data could provide meaningful upside for Galapagos shares even after the stock's 25% move up over the past three weeks, keeps a Buy rating and $64 fair value estimate on the stock.
09/22/16
LEER
09/22/16
NO CHANGE
LEER
Outperform
Gilead trial suspension another blow to R&D strategy, says Leerink
Leerink analyst Geoffrey Porges believes Gilead's suspension of Phase 2/3 for GS-5745, its anti-matrix metalloproteinase 9 anti-body for the treatment of ulcerative colitis, is unlikely to significantly impact revenue forecasts for the company. However, he sees the announcement as another blow to the sentiment about the company's R&D prospects and investor sentiment. Further, Porges notes that GS-5745 was one of the five proof-of-concept molecules in Phase 2 development that offered opportunity for some offset to Gilead's "increasingly challenged" core businesses. He reiterates an Outperform rating on the shares.
09/27/16
09/27/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Gilead (GILD) downgraded to Market Perform from Outperform at Leerink with analyst Geoffrey Porges saying he's now "outright bearish" on the company's Hepatitis C virus business. 2. J.M. Smucker (SJM) downgraded to Neutral from Outperform at Credit Suisse with analyst Robert Moskow saying that while the company raised its cost savings target as expected, he underestimated the hit to sales from difficult comparisons. 3. Discovery (DISCA) and Scripps Networks (SNI) downgraded to Sell from Neutral at MoffettNathanson. 4. Carter's (CRI) downgraded to Market Perform from Outperform at Wells Fargo with analyst Ike Boruchow saying his quarter-to-date store checks indicate "choppy" retail traffic trends and "deeper" pricing/promotional pressure. 5. Dollar Tree (DLTR) downgraded to Underweight from Neutral at Atlantic Equities with analyst Sam Hudson saying the second half comp inflection expected by consensus is "too demanding" and he expects multiple contraction if Family Dollar does not turn around. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MRK Merck
$62.41

0.5 (0.81%)

09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.
08/15/16
BERN
08/15/16
NO CHANGE
BERN
Survey of MDs suggest Merck's Keytruda being underestimated, says Bernstein
After Bernstein surveyed a total of 79 U.S. and EU doctors, analyst Tim Anderson says the impact of recent trials of Merck's (MRK) Keytruda and Bristol-Myers' (BMY) Opdivo will be "greater than many (investors) expect." Anderson says that the survey indicates that the positive implications on Merck and the negative impact on Bristol-Myers will not just be "a near-term phenomenon." The analyst continues to expect the impact of the recent data to be greater than the consensus outlook. He keeps a $74 price target and Outperform rating on Merck and a Market Perform rating on Bristol-Myers.
08/19/16
UBSW
08/19/16
NO CHANGE
Target $70
UBSW
Buy
Merck price target raised to $70 from $62 at UBS
UBS analyst Marc Goodman raised his price target on Merck (MRK) to $70 from $62 as he updated his model to account for a more favorable Keytruda opportunity following the failed CheckMate-026 trial at Bristol-Myers (BMY). The analyst also feels investors do not give enough credit to Merck's Januvia franchise or the potential for growth opportunity from the pipeline. Goodman reiterated his Buy rating on Merck shares.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
ABBV AbbVie
$63.07

0.25 (0.40%)

09/08/16
JPMS
09/08/16
DOWNGRADE
Target $73
JPMS
Neutral
AbbVie downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Chris Schott downgraded AbbVie (ABBV) to Neutral citing the stock's 10% rally year-to-date and limited near-term catalysts. AbbVie's profile is now better reflected at current valuation levels, Schott tells investors in a research note. He lowered his price target for the shares to $73 from $75. The analyst coupled the downgrade with an upgrade this morning of Eli Lilly (LLY) to Overweight.
09/02/16
09/02/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AbbVie (ABBV) initiated with an Outperform at Raymond James. 2. Spark Therapeutics (ONCE) initiated with a Buy at Stifel. 3. Cornerstone OnDemand (CSOD) initiated with an Overweight at Piper Jaffray. 4. UR-Energy (URG) initiated with an Outperform at FBR Capital. 5. Energy Transfer Equity (ETE) reinstated with an Overweight at JPMorgan. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/01/16
RAJA
09/01/16
INITIATION
Target $82
RAJA
Outperform
AbbVie initiated with an Outperform at Raymond James
Target $82.
07/14/16
JEFF
07/14/16
NO CHANGE
JEFF
AbbVie remains Jefferies' Top Pick in Global Pharma
Jefferies analyst Jeffrey Holford says AbbVie (ABBV) remains his firm's Top Pick in Global Pharmaceuticals, followed by Eli Lilly (LLY), Novartis (NVS), GlaxoSmithKline (GSK) and Zoetis (ZTS). The analyst this morning upgraded GSK to Buy from Hold. Holford also remains positive on Roche (RHHBY), Abbott (ABT) and Pfizer (PFE). The analyst's least preferred names are Novo Nordisk (NVO), Johnson & Johnson (JNJ) and Merck (MRK). The Q2 earnings season offers "few clear beat and raise" stories and looks weakest for AstraZeneca (AZN) against preliminary consensus, Holford tells investors in a pre-earnings research note.

TODAY'S FREE FLY STORIES

AXP

American Express

$79.71

0.2 (0.25%)

, MAT

Mattel

$26.10

0.43 (1.68%)

04:55
02/19/17
02/19
04:55
02/19/17
04:55
Conference/Events
Toy Industry Association to hold fair »

International Toy Fair…

AXP

American Express

$79.71

0.2 (0.25%)

MAT

Mattel

$26.10

0.43 (1.68%)

HAS

Hasbro

$98.50

0.86 (0.88%)

COST

Costco

$175.86

0.11 (0.06%)

AMZN

Amazon.com

$845.07

0.93 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 28

    Feb

  • 14

    Mar

  • 19

    Mar

  • 28

    Mar

QUNR

Qunar

$30.88

-0.14 (-0.45%)

15:28
02/18/17
02/18
15:28
02/18/17
15:28
Conference/Events
Qunar to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

REG

Regency Centers

$69.75

0.23 (0.33%)

, EQY

Equity One

$31.29

0.16 (0.51%)

15:21
02/18/17
02/18
15:21
02/18/17
15:21
Conference/Events
Equity One to host special shareholder meeting »

Special Shareholder…

REG

Regency Centers

$69.75

0.23 (0.33%)

EQY

Equity One

$31.29

0.16 (0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

EQY

Equity One

$31.29

0.16 (0.51%)

, REG

Regency Centers

$69.75

0.23 (0.33%)

15:18
02/18/17
02/18
15:18
02/18/17
15:18
Conference/Events
Regency Centers to host special shareholder meeting »

Special Shareholder…

EQY

Equity One

$31.29

0.16 (0.51%)

REG

Regency Centers

$69.75

0.23 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$7.05

0.03 (0.43%)

, ELNK

EarthLink

$5.63

-0.01 (-0.18%)

15:12
02/18/17
02/18
15:12
02/18/17
15:12
Conference/Events
EarthLink to host special shareholder meeting »

Special Shareholder…

WIN

Windstream

$7.05

0.03 (0.43%)

ELNK

EarthLink

$5.63

-0.01 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 01

    Mar

  • 06

    Mar

ELNK

EarthLink

$5.63

-0.01 (-0.18%)

, WIN

Windstream

$7.05

0.03 (0.43%)

15:09
02/18/17
02/18
15:09
02/18/17
15:09
Conference/Events
Windstream to host special shareholder meeting »

Virtual Special…

ELNK

EarthLink

$5.63

-0.01 (-0.18%)

WIN

Windstream

$7.05

0.03 (0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 06

    Mar

HNR

Harvest Natural

14:50
02/18/17
02/18
14:50
02/18/17
14:50
Conference/Events
Harvest Natural to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PH

Parker-Hannifin

$153.89

-0.52 (-0.34%)

, CLC

Clarcor

14:30
02/18/17
02/18
14:30
02/18/17
14:30
Conference/Events
Clarcor to host special shareholder meeting »

Special Shareholder…

PH

Parker-Hannifin

$153.89

-0.52 (-0.34%)

CLC

Clarcor

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

AZN

AstraZeneca

$29.16

0.4 (1.39%)

, BAYRY

Bayer

$113.29

0.05 (0.04%)

04:55
02/18/17
02/18
04:55
02/18/17
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2017 Genitourinary…

AZN

AstraZeneca

$29.16

0.4 (1.39%)

BAYRY

Bayer

$113.29

0.05 (0.04%)

BMY

Bristol-Myers

$54.59

0.31 (0.57%)

ESALY

Eisai

$54.40

0.205 (0.38%)

EXEL

Exelixis

$23.12

0.47 (2.08%)

GHDX

Genomic Health

$29.11

0.61 (2.14%)

MRK

Merck

$65.39

0.13 (0.20%)

MYGN

Myriad Genetics

$18.62

1.35 (7.82%)

NVS

Novartis

$77.20

0.47 (0.61%)

OPK

OPKO Health

$8.81

0.06 (0.69%)

PFE

Pfizer

PGNX

Progenics

$10.62

0.08 (0.76%)

SNY

Sanofi

$43.16

-0.38 (-0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 23

    Feb

  • 27

    Feb

  • 01

    Mar

  • 02

    Mar

  • 08

    Mar

  • 09

    Mar

  • 15

    Mar

  • 17

    Mar

  • 23

    Mar

  • 29

    Mar

  • 01

    Apr

  • 10

    May

  • 27

    May

  • 14

    Jun

  • 26

    Jun

MDT

Medtronic

$78.88

0.89 (1.14%)

, NVO

Novo Nordisk

$35.46

0.02 (0.06%)

04:55
02/18/17
02/18
04:55
02/18/17
04:55
Conference/Events
Kenes International Organizers to hold a conference »

10th International…

MDT

Medtronic

$78.88

0.89 (1.14%)

NVO

Novo Nordisk

$35.46

0.02 (0.06%)

RHHBY

Roche

$30.53

0.02 (0.07%)

ABT

Abbott

$44.69

0.49 (1.11%)

SNY

Sanofi

$43.16

-0.38 (-0.87%)

LLY

Eli Lilly

$80.39

0.35 (0.44%)

DXCM

Dexcom

$81.89

0.5 (0.61%)

JNJ

Johnson & Johnson

$118.86

0.78 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 23

    Feb

  • 24

    Feb

  • 24

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 06

    Mar

  • 07

    Mar

  • 09

    Mar

  • 17

    Mar

  • 21

    Mar

  • 27

    Mar

  • 29

    Mar

  • 19

    Apr

  • 26

    Jun

AXP

American Express

$79.71

0.2 (0.25%)

, MAT

Mattel

$26.10

0.43 (1.68%)

04:55
02/18/17
02/18
04:55
02/18/17
04:55
Conference/Events
Toy Industry Association to hold fair »

International Toy Fair…

AXP

American Express

$79.71

0.2 (0.25%)

MAT

Mattel

$26.10

0.43 (1.68%)

HAS

Hasbro

$98.50

0.86 (0.88%)

COST

Costco

$175.86

0.11 (0.06%)

AMZN

Amazon.com

$845.07

0.93 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 28

    Feb

  • 14

    Mar

  • 19

    Mar

  • 28

    Mar

PKY

Parkway

$21.58

0.08 (0.37%)

18:20
02/17/17
02/17
18:20
02/17/17
18:20
Hot Stocks
Parkway to sell 49% interest in Houston Greenway portfolio for $512.1M »

Parkway announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 01

    Mar

VIA

Viacom

$47.00

-0.2 (-0.42%)

, VIAB

Viacom

$43.99

-0.17 (-0.38%)

18:15
02/17/17
02/17
18:15
02/17/17
18:15
Periodicals
Paramount CEO Brad Grey to leave studio as early as next week, Reuters says »

Brad Grey, chairman and…

VIA

Viacom

$47.00

-0.2 (-0.42%)

VIAB

Viacom

$43.99

-0.17 (-0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

MNTA

Momenta

, PFE

Pfizer

18:03
02/17/17
02/17
18:03
02/17/17
18:03
Hot Stocks
Momenta: Sandoz partner Pfizer receives FDA warning letter »

Momenta Pharmaceuticals…

MNTA

Momenta

PFE

Pfizer

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 02

    Mar

  • 09

    Mar

  • 17

    Mar

  • 23

    Mar

  • 01

    Apr

CI

Cigna

$143.56

-1.77 (-1.22%)

, ANTM

Anthem

$160.25

-3.52 (-2.15%)

17:53
02/17/17
02/17
17:53
02/17/17
17:53
Periodicals
Cigna claims Anthem attempted to harm its business, Bloomberg says »

Cigna (CI) has accused…

CI

Cigna

$143.56

-1.77 (-1.22%)

ANTM

Anthem

$160.25

-3.52 (-2.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCMP

Sucampo

$11.80

0.05 (0.43%)

, NILE

Blue Nile

17:50
02/17/17
02/17
17:50
02/17/17
17:50
Hot Stocks
Sucampo to replace Blue Nile in the S&P 600 as of February 23 open »

Sucampo Pharmaceuticals…

SCMP

Sucampo

$11.80

0.05 (0.43%)

NILE

Blue Nile

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

VRML

Vermillion

$1.75

0.08 (4.79%)

17:39
02/17/17
02/17
17:39
02/17/17
17:39
Hot Stocks
Jack Schuler raises stake in Vermillion to 19.6% »

As of the date hereof,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SITO

SITO Mobile

$2.29

0.08 (3.62%)

17:34
02/17/17
02/17
17:34
02/17/17
17:34
Hot Stocks
SITO Mobile announces Jerry Hug resigned as CEO, names O'Connell interim »

Effective February 1,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 29

    Mar

CEMI

Chembio Diagnostics

$6.05

0.05 (0.83%)

17:32
02/17/17
02/17
17:32
02/17/17
17:32
Hot Stocks
Breaking Hot Stocks news story on Chembio Diagnostics »

ARS Investment Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTX

BioTime

17:31
02/17/17
02/17
17:31
02/17/17
17:31
Hot Stocks
Broadwood raises stake in BioTime to 24.5% »

Broadwood Partners,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

AHP

Ashford Hospitality Prime

$13.39

0.19 (1.44%)

17:30
02/17/17
02/17
17:30
02/17/17
17:30
Hot Stocks
Breaking Hot Stocks news story on Ashford Hospitality Prime »

Sessa Capital cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

HIIQ

Health Insurance Innovations

17:28
02/17/17
02/17
17:28
02/17/17
17:28
Hot Stocks
Breaking Hot Stocks news story on Health Insurance Innovations »

Patrick McNamee reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

HAR

Harman

$111.01

0.03 (0.03%)

, SSNLF

Samsung

17:28
02/17/17
02/17
17:28
02/17/17
17:28
Hot Stocks
Harman holders vote to approve Samsung deal »

According to a regulatory…

HAR

Harman

$111.01

0.03 (0.03%)

SSNLF

Samsung

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 28

    Mar

TST

TheStreet

$0.81

0.01 (1.25%)

17:21
02/17/17
02/17
17:21
02/17/17
17:21
Hot Stocks
Breaking Hot Stocks news story on TheStreet »

Raging Capital cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRK

Comstock Resources

$10.10

-0.65 (-6.05%)

17:17
02/17/17
02/17
17:17
02/17/17
17:17
Hot Stocks
Carl Westcott raises stake in Comstock Resources to 8.67% from 7.13% »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.